Artelo Biosciences

63 articles with Artelo Biosciences

• Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th

  5/16/2022

  Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL) , a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright Global Investment Conference which is being held on May 23- May 26, 2022 at the Fontainebleau Miami Beach Hotel.

• Artelo Biosciences to Present at MicroCap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th

  5/13/2022

  Artelo Biosciences, Inc. announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually May 16th - 20th, 2022.

• Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

  5/12/2022

  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the three months ending March 31, 2022.

• Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia

  4/13/2022

  Artelo Biosciences, Inc. today announced that ART27.13, a peripherally selective G-Protein Coupled Receptor (GPCR) full agonist currently in clinical development for cancer-related anorexia.

• Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In CancerNew Potential Uses of ART26.12 for Treating Tumors

  3/28/2022

  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that the Company has entered into a second collaboration with Richard K. Porter, Ph.D., of the School of Biochemistry & Immunology at Trinity College Dublin, Ireland.

• Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th

  3/22/2022

  Artelo Biosciences, Inc. announced it has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

• Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update

  3/21/2022

  Artelo Biosciences, Inc. today reported financial and operating results for the four month transitional period from September 1, 2021 to December 31, 2021 and provided a business update.

• Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update

  1/12/2022

  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year ended November 30, 2021 and provided a business update.

• Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update

  11/29/2021

  Artelo Biosciences, Inc., a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, reported financial and operating results for the fiscal year ended August 31, 2021 and provided a business update.

• Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/8/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

• Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines

  8/4/2021

  Artelo Biosciences, Inc.  today announced the publication of study results in Medical Cannabis and Cannabinoids, a peer-reviewed journal.

• Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021

  7/21/2021

  Artelo Biosciences, Inc. today announced that Ladenburg Thalmann & Co. Inc. will host an R&D showcase focused on the Phase 1b/2a Cancer Appetite Recovery Study (“CAReS”), evaluating the Company’s lead drug candidate, ART27.13.

• Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update

  7/12/2021

  Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end $10.0 Million of Cash and Cash Equivalents as of May 31, 2021

• Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th

  7/7/2021

  Artelo Biosciences, Inc. today announced that management will be presenting and hosting 1x1 meetings during the Ladenburg Thalmann Healthcare Conference taking place virtually July 13-14, 2021.

• Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium

  6/22/2021

  Dr. Andrew Yates to Present Poster on the Company’s ART27.13 Cancer Appetite Recovery Study Prof. Saoirse O’Sullivan to Present Poster Related to Artelo’s ART12.11

• Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th

  6/2/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.

• Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update

  4/13/2021

  Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK Reported Positive Pre-Clinical Data Associated with Artelo’s Proprietary CBD Cocrystal $11.2 Million of Cash and Cash Equivalents and Marketable Securities as of February 28, 2021

• Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

  4/12/2021

  Initial safety data expected from CAReS Study before end of 2021 Targeting multi-billion market with no approved therapies for cancer-related anorexia

• Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development

  3/19/2021

  Detection of elevated FABP5 associated with additional tumor types suggests  the target for ART26.12 may be more broadly relevant in cancer therapy Alderley Park Oncology Development Program is a UK program  designed to develop and progress innovative oncology projects

• Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd

  3/11/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation March 23rd @ 1:00PM ET